Everolimus-eluting Versus Sirolimus-eluting Stents For Treatment Of Coronary Atherosclerotic Heart Disease:a Meta-analysis

Objective: To evaluate the efficacy and safety of everolimus-eluting stents（EES）in the treatment of coronary atherosclerotic heart disease.Methods: Electronic database searching was performed on Pubmed,Embase, Cochrane library, CBMdisc to collect controlled trials about EES vssirolimus-eluting stents（SES） for the treatment of coronary atheroscleroticheart disease. The methodological quality of included studies was assessedaccording to Cochrane handbook5.1.0, statistical analysis was performed usingRevMan5.1software. Results:8RCTs，11914patients were included(EES=6315, SES=5599).The risk of major adverse coronary events （MACE）（RR=1.17,95%CI0.80～1.70，P=0.13）,cardiac death(RR=0.80,95%CI0.59～1.07，P=0.13), myocardialinfarction （MI）（RR=0.78,95%CI0.59～1.04， P=0.09）, target lesionrevascularization （TLR）（RR=0.80,95%CI0.61～1.06，P=0.12）,and stentthrombosis（RR=0.76,95%CI0.24～2.38，P=0.64）after12-month placement ofEES or SES were not significantly different between these two kinds of stents.However, the EES group demonstrated a lower incidence of both MI（RR=0.71,95%CI0.54～0.93，P=0.01）and TLR（RR=0.76,95%CI0.63～0.92，P=0.006） than the SES group during follow-up to36months.Conclusions: This meta analysis suggests that the use of EES may benoninferior to SES.